The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis.

Nanna Nyholm Anne Danø Henrik SchnackGiorgio Lorenzo Colombo

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

Our study showed that using brodalumab as a first-line therapy to treat moderate-to-severe psoriasis in both Italy and Germany leads to the most cost-effective treatment sequence, when compared to all possible combinations of anti-IL17s over a five-year time horizon. In addition, we found that treatment discontinuation and switching are important factors when assessing the cost-effectiveness of biologic therapies.

Keyphrases

rheumatoid arthritis
early onset
mesenchymal stem cells
drug induced
amino acid
atopic dermatitis
smoking cessation